Small-cell lung cancer: Current therapy and novel agents

ONCOLOGY

Volumn 19, Issue 1, 2005, Pages 47-52

  Horiike, Atsushi ^a   Saijo, Nagahiro ^b,c  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMRUBICIN; CAMPTOTHECIN DERIVATIVE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IMATINIB; IRINOTECAN; MARIMASTAT; NAVELBINE; OBLIMERSEN; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TOPOTECAN; VINCRISTINE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; VP P PROTOCOL; VP-P PROTOCOL;

CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGISTRY; CANCER RELAPSE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DIARRHEA; DNA REPLICATION; DRUG FATALITY; DRUG MECHANISM; DRUG POTENTIATION; GERIATRIC PATIENT; HUMAN; LUNG SMALL CELL CANCER; LUNG TOXICITY; META ANALYSIS; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ADULT; AGE; AGED; CANCER STAGING; DOSE RESPONSE; LUNG TUMOR; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; RADIATION RESPONSE; SMALL CELL CARCINOMA;

ADULT; AGE FACTORS; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, SMALL CELL; CISPLATIN; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; ETOPOSIDE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS;

EID: 17844382720     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Kristjansen PE, Hansen HH: Management of small cell lung cancer: A Summary of the Third International Association for the Study of Lung Cancer Workshop on Small Cell Lung Cancer. J Natl Cancer Inst 82:263-266, 1990.
2. Pujol JL, Carestia L, Daures JP: Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen vs a regimen without this alkylating agent. Br J Cancer 83:8-15, 2000.
3. Berghmans T, Paesmans M, Mascaux C, et al: A meta-analysis of the role of etoposide (ETP) and cisplatin (CDDP) in small cell lung cancer (SCLC) with a methodology assessment (abstract). Eur J Cancer 35(suppl):s248, 1999.
4. Chute, JP, Chen, T, Feigal E, et al: Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: Perceptible progress. J Clin Oncol 17:1794-1801, 1999.
5. Negoro S, Fukuoka M, Niitani H, et al: Phase II study of CPT-11, new camptothecin derivative, in small cell lung cancer (SCLC) (abstract). Proc Am Soc Clin Oncol 10:241a, 1991.
6. Masuda N, Fukuoka M, Kusunoki Y, et al: CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225-1229, 1992.
7. Smyth JF, Smith IE, Sessa C, et al: Activity of docetaxel (Taxotere) in small cell lung cancer. Eur J Cancer 30A:1058-1060, 1994.
8. Cormier Y, Eisenhauer E, Muldal A, et al: Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 75:283-285, 1994.
9. Ettinger D, Finkelstein D, Ritch P, et al: Randomized trial of single agents vs combination chemotherapy in extensive stage small cell lung cancer (SCLC) (abstract 988). Proc Am Soc Clin Oncol 11:295a, 1992.
10. Ettinger D, Finkelstein DM, Sarma RP, et al: Phase II study of paclitaxel in patients with extensive-disease small cell lung cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 13:1430-1435, 1995.
11. Kirschling RJ, Jung SH, Jett JR, et al: A phase II trial of Taxol and GCSF in previously untreated patients with extensive stage small cell lung cancer (SCLC) (abstract 1076). Proc Am Soc Clin Oncol 13:326a, 1994.
12. Ardizzoni A, Hansen H, Dombernowsky P, et al: Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 15:2090-2096, 1997.
13. Schiller JH, Kim K, Hutson P, et al: Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: An Eastem Cooperative Oncology Group Trial. J Clin Oncol 14:2345-2352, 1996.
14. Jassem J, Karnlcka-Mlodkowska H, Van Pottelsberghe CH, et al: Phase II study of vinorelbine (navelbine) in previously treated small cell lung cancer patients. Eur J Cancer 29A:1720-1722, 1993.
15. Furuse K, Kubota K, Kawahara M, et al: Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Oncology 53:169-172, 1996.
16. Kudoh S, Takada M, Masuda N, et al: Enhanced anti-tumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts. Jpn J Cancer Res 84:203-207, 1993.
17. Masumoto N, Nakano S, Esaki T, et al: Inhibition of cis- diamminedichloroplatinum (II)-induced DNA interstrand cross-link removal by 7-ethyl-10-hydroxy-camptothecin in HST-1 human squamous-carcinoma cells. Int J Cancer 62:70-75, 1995.
18. Pei XH, Nakanishi Y, Takayama K, et al: Effect of CPT-11 in combination with other anticancer agents in lung cancer cells. Anticancer Drugs 8:231-237, 1997.
19. Kudoh S, Fujiwara Y, Takada Y, et al: Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. J Clin Oncol 16:1068-1074, 1998.
20. Noda K, Nishiwaki Y, Kawahara M, et al: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85-91, 2002.
21. Sandler A, Langer C, Bunn PA, et al: Interim safety analysis of irinotecan and cisplatin combination chemotherapy for previously untreated extensive small cell lung cancer (abstract 2537). Proc Am Soc Clin Oncol 22:631, 2003.
22. Yana T, Negoro S, Takada Y, et al: Phase II study of amrubicin (SM-5887), a 9-aminoamhracycline, in previously untreated patients with extensive stage small-cell lung cancer (ESSCLC): A west Japan lung cancer group trial (abstract). Proc Am Soc Clin Oncol 17:450a, 1998.
23. Negoro S, Ohe Y, Matsui K, et al: Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive stage small cell lung cancer (ED-SCLC) (abstract 2608). Proc Am Soc Clin Oncol 22:648, 2003.
24. Kelly K, Lovato L, Bunn PA Jr, et al: Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: A phase II trial of the Southwest Oncology Group. Clin Cancer Res 7:2325-2329, 2001.
25. Niell HB, Herndon JE, Miller AA, et al: Randomized phase III intergroup trial (CALGB 9732) of etoposide (ETP) and cisplatin (DDP) with or without paclitaxel (TAX) and G-CSF in patients with extensive stage small cell lung cancer (ED-SCLC) (abstract 1169). Proc Am Soc Clin Oncol 21:293a, 2002.
26. Sekine I, Nishiwaki Y, Noda K, et al: Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI). Ann Oncol 14:709-714, 2003.
27. Shepherd FA, Giaccone G, Seymour L, et al: Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: A trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 15:4434-4439, 2002.
28. Rudin C, Kosloff M, Edelman MJ, et al: Phase I study of G3139 (oblimersen sodium), carboplatin, and etoposide in previously untreated extensive stage small cell lung cancer (SCLC) (abstract 2538). Proc Am Soc. Clin Oncol 22:631, 2003.
29. Dowell J, Amirkhan RH, Lai WS, et al: Survival in small cell lung cancer (SCLC) is independent of vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (COX-2) expression (abstract 2541). Proc Am Soc Clin Oncol 22:632, 2003.
30. von Pawel J, Schiller JH, Shepherd FA, et al: Topotecan vs cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17:658-667, 1999.
31. Masuda N, Fukuoka M, Kusunoki Y, et al: CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225-1229, 1992.
32. Smit EF, Fokkema E, Biesma B, et al: A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer 77:347-351, 1998.
33. Girling DJ: Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: A stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party. Lancet 348:563-566, 1996.
34. Souhami RL, Spiro SG, Rudd RM, et al: Five-day oral etoposide treatment for advanced small-cell lung cancer: Randomized comparison with intravenous chemotherapy. J Natl Cancer Inst 89:577-580, 1997.
35. Warde P, Payne D: Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 10:890-895, 1992.
36. Pignon JP, Arriagada R, Ihde DC, et al: A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327:1618-1624, 1992.
37. Murray N, Coldman A: The relationship between the thoracic irradiation timing and long-term survival in combined modality therapy of limited stage small cell lung cancer (LSCLC) (abstract 1099). Proc Am Soc Clin Oncol 14:360a, 1995.
38. Turrisi AT, Kim K, Blum R, et al: Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340:265-271, 1999.